Slide Show: Highlights From the 2015 ASCO Breast Cancer Symposium

References:

• Caggiano V, Parise C. Racial/ethnic disparities in HER2-positive breast cancer in the era of adjuvant trastuzmab. Presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium; Abstract 139.
• Hong JJ, Seksenyan A, Yuan X. et al. TOX3 as a novel biomarker in luminal B breast cancer. Presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium; Abstract 130.
• Yadav S, Fulbright J, Dreyfuss H,  et al. Outcomes of retesting BRCA-negative patients using multigene panels. Presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium; Abstract 23.
• Shafaee MN, Gutierrez-Barrera AM, Lin HL, Arun B. Aromatase inhibitors and the risk of contralateral breast cancer in BRCA mutation carriers. Presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium; Abstract 3.
• Hassan SN, Esch A, Heiser L, Gray JW. Biological indicators of response and resistance to PARP inhibition in BRCA wild-type breast cancer. Presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium; Abstract 125.
• Chan A, Martin M, Von Minckwitz G. et al. Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial. Presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium; Abstract 117.